Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.49 |
| ▸ | MME | P08473 | 3/20 | 0.49 |
| ▸ | ACE | P12821 | 3/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.48 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.48 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.48 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.47 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.46 |
| ▸ | CHRNG | P07510 | 1/20 | 0.46 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.46 |
| ▸ | CHRND | Q07001 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5495776 | 1.00 | FOLH1 (0.50) | FOLH1PTPN1MMEACECHRNB2 | |
| SCHEMBL5492379 | 0.95 | PTPN1 (0.52) | FOLH1PTPN1MMEACECHRNB2 | |
| SCHEMBL5496771 | 0.95 | PTPN1 (0.52) | FOLH1PTPN1MMEACECHRNB2 | |
| SCHEMBL5498667 | 0.95 | CHRNB2 (0.53) | FOLH1PTPN1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL5488901 | 0.86 | CHRNB2 (0.46) | FOLH1PTPN1MMECHRNB2CHRNB4 | |
| SCHEMBL5499120 | 0.86 | CHRNB2 (0.46) | FOLH1PTPN1MMECHRNB2CHRNB4 | |
| SCHEMBL14598274 | 0.86 | FOLH1 (0.44) | FOLH1PTPN1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL5496941 | 0.85 | CHRNB2 (0.46) | FOLH1PTPN1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL5492131 | 0.85 | CHRNB2 (0.46) | FOLH1PTPN1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL14598248 | 0.83 | FOLH1 (0.48) | FOLH1PTPN1MMEACECHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070004644-A1 | Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia | SIRCAR JAGADISH C | 2007-01-04 | — | — | US | disclosed |
| US-20070004644-A1 | Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia | SIRCAR JAGADISH C | 2007-01-04 | — | — | US | disclosed |
| US-20070004644-A1 | Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia | SIRCAR JAGADISH C | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004644-A1 | Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia | CETP, LDLR, NPC1L1 | FOLH1 1672/4885PTPN1 4278/4885MME 2615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.